AMGN · News · 20260817N

Guidance and Outlook

AMGEN INC · 2026-08-17 · Importance 75 · Surprise 60 · In source text

Amgen raised its full-year 2026 revenue guidance to $38.2 billion-$39.4 billion, according to third-party reporting on August 17, 2026. The company reportedly reaffirmed its fiscal 2026 EPS guidance in connection with its second-quarter update. The revenue outlook represents management’s forward view for the full year and exceeds the materiality threshold of $302 million.

Key facts

• Amgen expects 2026 revenue to be between $38.2 billion and $39.4 billion. source
• KBC Group NV increased its stake in Amgen Inc. by 51.7% in the second quarter, acquiring an additional 130,497 shares and bringing its total holdings to 382,676 shares valued at $138.57 million. source
• Amgen plans an upcoming Science and Innovation Center in Hyderabad. source
• Convergence Financial LLC boosted its stake in shares of Amgen Inc. by 91.9% in the undefined quarter, owning 3,673 shares after buying an additional 1,759. source
• Amgen exceeded earnings and revenue expectations for the quarter and reaffirmed its fiscal 2026 EPS guidance. source
• 111 Capital reduced its stake in Amgen Inc. by 45.8% in the second quarter and now holds 3,851 shares valued at approximately $1.40 million. source
• Janney Montgomery Scott LLC reduced its stake in Amgen Inc. by 3.6% in the second quarter, selling 14,784 shares but retaining over 400,000 shares valued at approximately $145.3 million. source
• HighTower Advisors LLC reduced its stake in Amgen Inc. by 0.5% in the second quarter, selling 4,063 shares and holding 816,257 shares valued at approximately $295.6 million. source

Impact estimates